Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout

Journal of Rheumatology

Volumn 32, Issue 10, 2005, Pages 1923-1927

  Alvarez Nemegyei, José ^a,d   Cen Pisté, Julio Cesar ^b   Medina Escobedo, Martha ^c   Villanueva Jorge, Salha ^c  

^a Clinical Epidemiology Research Unit   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c Hospital General O'Horan   (Mexico)

^d NONE   (Mexico)

Author keywords

Gout; Musculoskeletal disability; Prognosis; Prognostic factors; Renal failure

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; CHOLESTEROL; COLCHICINE; GLUCOCORTICOID; GLUCOSE; NONSTEROID ANTIINFLAMMATORY AGENT; TRIACYLGLYCEROL; URIC ACID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALCOHOLISM; ARTICLE; BIOCHEMISTRY; BODY MASS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; EDUCATION; ELDERLY CARE; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; GOUT; GOUT TOPHI; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INCOME; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OBESITY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RISK FACTOR; SMOKING HABIT; SOCIOECONOMICS; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 26444555573     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Wortmann RL, Kelley WN. Gout and hyperuricemia. In: Ruddy S, Harris ED, Sledge CB, editors. Kelley's textbook of rheumatology. 6th ed. Philadelphia: W.B. Saunders; 2001:1339-76.
2. Becker MA. Clinical manifestations and diagnosis of gout. In: Rose BD, editor. UpToDate. Wellesley, MA: UpToDate; 2001. Available from: http://patients.uptodate.com/topic.asp?file=crystald/26808. Accessed June 9, 2005.
3. Rose BR, Becker MA. Uric acid renal disease. In: Rose BD, editor. UpToDate. Wellesley, MA: UpToDate; 2001. Available from: http://patients. uptodate.com/topic.asp?file=renldis/13851&title=Gout. Accessed June 9, 2005.
4. Becker MA. Treatment of gout. In: Rose BD, editor. UpToDate. Wellesley, MA: UpToDate; 2001. Available from: http://patients.uptodate.com/topic.asp?file= arth_rhe/5421#6. Accessed June 9, 2005.
5. Cohen MG, Emmerson BT. Gout. In: Klippel JH, Dieppe PA, editors. Rheumatology. Philadelphia: Mosby; 1995.
6. Valat JP, Fouquet B. Gout. Epidemiology, physiopathology, diagnosis, course, prognosis, principles of treatment [French]. Rev Prat 1992;42:1307-11.
7. Mertz DP. Changes in the epidemiology, symptomatology and prognosis of gout [German]. Versicherungsmedizin 1992;44:10-3.
8. Iwatani M, Nishioka K. The prognosis of gout and hyperuricemia - the effect of the treatment on prognosis [Japanese]. Nippon Rinsho 1991;49:1124-30.
9. Siniachenko OV, Diadyk AI, Oberemchenko IV, Vasilenko IV, Dikshtein EA. Course and prognosis of nephropathy in gout. [Russian]. Ter Arkh 1986;58:29-32.
10. Sanwald R. Clinical aspects and prognosis of hyperuricemia and gout [German]. Lebensversicher Med 1983;35:65-8.
11. Lavicka J. Prognosis and prevention of gout complications [German]. Beitr Rheumatol 1972;18:86-8.
12. Zollner N, Grobner W. Improvement of gout prognosis by suitable therapy [German]. Lebensversicher Med 1971;23:125-7.
13. Steinbrocker O. Prognosis for employability in the major arthritides rheumatoid arthritis, osteoarthritis and gout. Pa Med 1969;72:82-5.
14. Raestrup O. Prognosis of gout. Evaluation in life insurance medicine [German]. Munch Med Wochenschr 1968;110:1249-55.
15. Darmawan J, Rasker JJ, Nuralim H. The effect of control and self-medication of chronic gout in a developing country: Outcome after 10 years. J Rheumatol 2003;30:2437-43.
16. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
17. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
18. Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcon-Segovia D. How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol 1993;11:117-21.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification [abstract]. Am J Kidney Dis 2002;39 Suppl 1:S1-266.
20. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
21. Levey AS, Greene T, Kusek KW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 2000;11:155A.
22. Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 2002;20:617-24.
23. Pincus T, Callahan LF, Burlhauser RV. Most chronic diseases are reported more frequently by individuals with fewer than 12 years of formal education in the age 18-64 United States population. J Chron Dis 1987;40:865-74.
24. Pincus T. Formal educational level. A marker for the importance of behavioral variables in the pathogenesis, morbidity, and mortality of most diseases? J Rheumatol 1988;15:1457-60.
25. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously. Predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986;13:841-5.
26. Pincus T, Callahan LF. Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. J Chron Dis 1985;38:973-84.
27. Callahan LF, Pincus T. Formal educational level as a significant marker of clinical status in rheumatoid arthritis. Arthritis Rheum 1988;31:1346-57.
28. Leigh JP, Fries JF. Education level and rheumatoid arthritis: evidence from five data centers. J Rheumatol 1991;18:24-34.
29. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology Oxford 2000;39 Suppl 1:24-9.
30. Ginzler EM, Diamond HS, Weiner M, et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 1982;25:601-11.
31. Swaak AJ, Nossent JC, Bronsveld W, et al. Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989;48:447-54.
32. Miller MH, Urowitz MB, Gladman DD, Killinger D. Systemic lupus erythematosus in males. Medicine 1983;62:327-34.
33. Ginzler EM, Schorn K. Outcome and prognosis in systemic lupus erythematosus. Rheum Dis Clin North Am 1988;14:67-78.
34. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus: Patient characteristics associated with poorer outcomes. Arthritis Rheum 1995;38:274-83.
35. Jacobsen S, Petersen J, Ullman S, et al. A multicentre study of 513 Danish patients with SLE. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol 1998;17:478-84.
36. Yu TF, Dorph DJ, Smith H. Hyperlipidemia in primary gout. Semin Arthritis Rheum 1978;7:233-44.
37. Vazquez-Mellado J, García CG, Vazquez SG, et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004;10:105-9.
38. Janssens HJEM, van de Lisdonk EH, Bor H, van den Hoogen HJM, Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract 2003;20:413-6.